Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Treatment
2.2. Statistical Analysis
3. Results
3.1. Patient Characteristics According to the LPT
3.2. Overall and Progression-Free Survival According to the LPT
3.3. Response to the Anti-EGFR Therapy in KRAS Wild-Type mCRC Patients
3.4. HER2 Expression
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Nagai, Y.; Kiyomatsu, T.; Gohda, Y.; Otani, K.; Deguchi, K.; Yamada, K. The primary tumor location in colorectal cancer: A focused review on its impact on surgical management. GHM 2021, 3, 386–393. [Google Scholar] [CrossRef]
- Ra, H.; Jeong, S.; Lee, H.; Chung, J.-W.; Kim, K.O.; Lee, W.-S.; Kim, J.; Kwon, K.A.; Kim, J.H. Clinicopathological Differences between Right and Left Colorectal Cancer by Sex. JCM 2024, 13, 2810. [Google Scholar] [CrossRef]
- Ramadan, M.; Alfayea, T.; Alsofyani, A.; Alyabsi, M.; Alhusseini, N.; Algarni, A.S. Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis. Cancer Treat. Res. Commun. 2022, 33, 100632. [Google Scholar] [CrossRef]
- Li, F.; Lai, M. Colorectal cancer, one entity or three. J. Zhejiang Univ. Sci. B 2009, 10, 219–229. [Google Scholar] [CrossRef] [PubMed]
- Tejpar, S.; Stintzing, S.; Ciardiello, F.; Tabernero, J.; Van Cutsem, E.; Beier, F.; Esser, R.; Lenz, H.-J.; Heinemann, V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017, 3, 194–201. [Google Scholar] [CrossRef] [PubMed]
- Loupakis, F.; Yang, D.; Yau, L.; Feng, S.; Cremolini, C.; Zhang, W.; Maus, M.K.H.; Antoniotti, C.; Langer, C.; Scherer, S.J.; et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J. Natl. Cancer Inst. 2015, 107, dju427. [Google Scholar] [CrossRef]
- Arnold, D.; Lueza, B.; Douillard, J.-Y.; Peeters, M.; Lenz, H.-J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J.-P.; Tabernero, J.; et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 2017, 28, 1713–1729. [Google Scholar] [CrossRef]
- Weiss, J.M.; Pfau, P.R.; O’Connor, E.S.; King, J.; LoConte, N.; Kennedy, G.; Smith, M.A. Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare Data. JCO 2011, 29, 4401–4409. [Google Scholar] [CrossRef] [PubMed]
- Mirón Fernández, I.; Mera Velasco, S.; Turiño Luque, J.D.; González Poveda, I.; Ruiz López, M.; Santoyo Santoyo, J. Right and Left Colorectal Cancer: Differences in Post-Surgical-Care Outcomes and Survival in Elderly Patients. Cancers 2021, 13, 2647. [Google Scholar] [CrossRef]
- Huyghe, J.R.; Harrison, T.A.; Bien, S.A.; Hampel, H.; Figueiredo, J.C.; Schmit, S.L.; Conti, D.V.; Chen, S.; Qu, C.; Lin, Y.; et al. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut 2021, 70, 1325–1334. [Google Scholar] [CrossRef] [PubMed]
- Nouri, R.; Hasani, A.; Masnadi Shirazi, K.; Alivand, M.R.; Sepehri, B.; Sotoudeh, S.; Hemmati, F.; Fattahzadeh, A.; Abdinia, B.; Ahangarzadeh Rezaee, M. Mucosa-Associated Escherichia coli in Colorectal Cancer Patients and Control Subjects: Variations in the Prevalence and Attributing Features. Can. J. Infect. Dis. Med. Microbiol. 2021, 2021, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Lei, S.; Ge, Y.; Tian, S.; Cai, B.; Gao, X.; Wang, N.; Wang, G.; Wang, L.; Wang, Z. Colorectal Cancer Metastases to Brain or Bone and the Relationship to Primary Tumor Location: A Population-Based Study. J. Gastrointest. Surg. 2020, 24, 1833–1842. [Google Scholar] [CrossRef] [PubMed]
- Jess, T.; Horváth-Puhó, E.; Fallingborg, J.; Rasmussen, H.H.; Jacobsen, B.A. Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study. Am. J. Gastroenterol. 2013, 108, 1869–1876. [Google Scholar] [CrossRef]
- Araki, K.; Furuya, Y.; Kobayashi, M.; Matsuura, K.; Ogata, T.; Isozaki, H. Comparison of Mucosal Microvasculature between the Proximal and Distal Human Colon. J. Electron. Microsc. 1996, 45, 202–206. [Google Scholar] [CrossRef]
- Kohoutova, D.; Smajs, D.; Moravkova, P.; Cyrany, J.; Moravkova, M.; Forstlova, M.; Cihak, M.; Rejchrt, S.; Bures, J. Escherichia colistrains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect. Dis. 2014, 14, 733. [Google Scholar] [CrossRef] [PubMed]
- Gao, Z.; Guo, B.; Gao, R.; Zhu, Q.; Qin, H. Microbiota disbiosis is associated with colorectal cancer. Front. Microbiol. 2015, 6, 20. [Google Scholar] [CrossRef]
- Missiaglia, E.; Jacobs, B.; D’Ario, G.; Di Narzo, A.F.; Soneson, C.; Budinska, E.; Popovici, V.; Vecchione, L.; Gerster, S.; Yan, P.; et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 2014, 25, 1995–2001. [Google Scholar] [CrossRef]
- Brouwer, N.P.M.; Van Der Kruijssen, D.E.W.; Hugen, N.; De Hingh, I.H.J.T.; Nagtegaal, I.D.; Verhoeven, R.H.A.; Koopman, M.; De Wilt, J.H.W. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. Ann. Surg. Oncol. 2020, 27, 1580–1588. [Google Scholar] [CrossRef]
- Bratei, A.A.; Stefan-van Staden, R.-I. The Importance of KRAS Quantification for a Clinicopathological Characterization in Colorectal Cancer Patients. MEDIN 2023, 1, 20–26. [Google Scholar] [CrossRef]
- Linardou, H.; Briasoulis, E.; Dahabreh, I.J.; Mountzios, G.; Papadimitriou, C.; Papadopoulos, S.; Bafaloukos, D.; Kosmidis, P.; Murray, S. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat. Rev. 2011, 37, 221–233. [Google Scholar] [CrossRef]
- Davis, A.A.; Cristofanilli, M. Detection of Predictive Biomarkers Using Liquid Biopsies. In Predictive Biomarkers in Oncology; Badve, S., Kumar, G.L., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 107–117. ISBN 978-3-319-95227-7. [Google Scholar]
- Schirripa, M.; Cohen, S.A.; Battaglin, F.; Lenz, H.-J. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin. Oncol. 2018, 45, 124–132. [Google Scholar] [CrossRef] [PubMed]
- Sjoquist, K.M.; Renfro, L.A.; Simes, R.J.; Tebbutt, N.C.; Clarke, S.; Seymour, M.T.; Adams, R.; Maughan, T.S.; Saltz, L.; Goldberg, R.M.; et al. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI J. Natl. Cancer Inst. 2018, 110, 638–648. [Google Scholar] [CrossRef] [PubMed]
- Cheng, X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes 2024, 15, 903. [Google Scholar] [CrossRef] [PubMed]
- Meric-Bernstam, F.; Hurwitz, H.; Raghav, K.P.S.; McWilliams, R.R.; Fakih, M.; VanderWalde, A.; Swanton, C.; Kurzrock, R.; Burris, H.; Sweeney, C.; et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019, 20, 518–530. [Google Scholar] [CrossRef] [PubMed]
- Iqbal, N.; Iqbal, N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int. 2014, 2014, 852748. [Google Scholar] [CrossRef]
- Achalla, L.S.V.; Shinde, R.K.; Jogdand, S.; Vodithala, S. Review of the Role of HER2/neu in Colorectal Carcinomas. Cureus 2022, 14, e25409. [Google Scholar] [CrossRef]
- Sartore-Bianchi, A.; Trusolino, L.; Martino, C.; Bencardino, K.; Lonardi, S.; Bergamo, F.; Zagonel, V.; Leone, F.; Depetris, I.; Martinelli, E.; et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016, 17, 738–746. [Google Scholar] [CrossRef]
- Poston, G.J.; Figueras, J.; Giuliante, F.; Nuzzo, G.; Sobrero, A.F.; Gigot, J.-F.; Nordlinger, B.; Adam, R.; Gruenberger, T.; Choti, M.A.; et al. Urgent Need for a New Staging System in Advanced Colorectal Cancer. JCO 2008, 26, 4828–4833. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network Washington: Clinical Practice Guidelines in Oncology, Inc. Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed on 28 January 2024).
- Siravegna, G.; Mussolin, B.; Buscarino, M.; Corti, G.; Cassingena, A.; Crisafulli, G.; Ponzetti, A.; Cremolini, C.; Amatu, A.; Lauricella, C.; et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015, 21, 795–801. [Google Scholar] [CrossRef]
- Lee, G.H.; Malietzis, G.; Askari, A.; Bernardo, D.; Al-Hassi, H.O.; Clark, S.K. Is right-sided colon cancer different to left-sided colorectal cancer?—A systematic review. Eur. J. Surg. Oncol. (EJSO) 2015, 41, 300–308. [Google Scholar] [CrossRef]
- Lee, H.; Sha, D.; Foster, N.R.; Shi, Q.; Alberts, S.R.; Smyrk, T.C.; Sinicrope, F.A. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann. Oncol. 2020, 31, 487–494. [Google Scholar] [CrossRef] [PubMed]
- Saberzadeh-Ardestani, B.; Foster, N.R.; Lee, H.E.; Shi, Q.; Alberts, S.R.; Smyrk, T.C.; Sinicrope, F.A. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]. Ann. Oncol. 2022, 33, 1159–1167. [Google Scholar] [CrossRef] [PubMed]
- Baran, B.; Mert Ozupek, N.; Yerli Tetik, N.; Acar, E.; Bekcioglu, O.; Baskin, Y. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterol. Res. 2018, 11, 264–273. [Google Scholar] [CrossRef]
- De Cuyper, A.; Van Den Eynde, M.; Machiels, J.-P. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. Clin. Color. Cancer 2020, 19, 65–72. [Google Scholar] [CrossRef] [PubMed]
- Boeckx, N.; Koukakis, R.; Op De Beeck, K.; Rolfo, C.; Van Camp, G.; Siena, S.; Tabernero, J.; Douillard, J.-Y.; André, T.; Peeters, M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies. Ann. Oncol. 2017, 28, 1862–1868. [Google Scholar] [CrossRef] [PubMed]
- Bustamante-Lopez, L.A.; Nahas, S.C.; Nahas, C.S.R.; Pinto, R.A.; Marques, C.F.S.; Cecconello, I. IS THERE A DIFFERENCE BETWEEN RIGHT- VERSUS LEFT-SIDED COLON CANCERS? DOES SIDE MAKE ANY DIFFERENCE IN LONG-TERM FOLLOW-UP? ABCD Arq. Bras. Cir. Dig. 2019, 32, e1479. [Google Scholar] [CrossRef]
- Venderbosch, S.; Nagtegaal, I.D.; Maughan, T.S.; Smith, C.G.; Cheadle, J.P.; Fisher, D.; Kaplan, R.; Quirke, P.; Seymour, M.T.; Richman, S.D.; et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clin. Cancer Res. 2014, 20, 5322–5330. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.; Ma, C.; Li, W. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn. Pathol. 2015, 10, 144. [Google Scholar] [CrossRef]
- Yalikong, A.; Li, X.-Q.; Zhou, P.-H.; Qi, Z.-P.; Li, B.; Cai, S.-L.; Zhong, Y.-S. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. IJN 2021, 16, 2323–2335. [Google Scholar] [CrossRef]
- Raghav, K.; Loree, J.M.; Morris, J.S.; Overman, M.J.; Yu, R.; Meric-Bernstam, F.; Menter, D.; Korphaisarn, K.; Kee, B.; Muranyi, A.; et al. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis. Oncol. 2019, 3, 1–13. [Google Scholar] [CrossRef]
- Hainsworth, J.D.; Meric-Bernstam, F.; Swanton, C.; Hurwitz, H.; Spigel, D.R.; Sweeney, C.; Burris, H.A.; Bose, R.; Yoo, B.; Stein, A.; et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. JCO 2018, 36, 536–542. [Google Scholar] [CrossRef] [PubMed]
- Ingold Heppner, B.; Behrens, H.-M.; Balschun, K.; Haag, J.; Krüger, S.; Becker, T.; Röcken, C. HER2/neu testing in primary colorectal carcinoma. Br. J. Cancer 2014, 111, 1977–1984. [Google Scholar] [CrossRef] [PubMed]
- Yagisawa, M.; Sawada, K.; Nakamura, Y.; Fujii, S.; Yuki, S.; Komatsu, Y.; Yoshino, T.; Sakamoto, N.; Taniguchi, H. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. Clin. Color. Cancer 2021, 20, 113–120.e1. [Google Scholar] [CrossRef] [PubMed]
- Puccini, A.; Lenz, H.-J.; Marshall, J.L.; Arguello, D.; Raghavan, D.; Korn, W.M.; Weinberg, B.A.; Poorman, K.; Heeke, A.L.; Philip, P.A.; et al. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist 2019, 24, 319–326. [Google Scholar] [CrossRef] [PubMed]
- Park, D.I.; Kang, M.S.; Oh, S.J.; Kim, H.J.; Cho, Y.K.; Sohn, C.I.; Jeon, W.K.; Kim, B.I.; Han, W.K.; Kim, H.; et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int. J. Color. Dis. 2007, 22, 491. [Google Scholar] [CrossRef] [PubMed]
- Siena, S.; Sartore-Bianchi, A.; Marsoni, S.; Hurwitz, H.I.; McCall, S.J.; Penault-Llorca, F.; Srock, S.; Bardelli, A.; Trusolino, L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann. Oncol. 2018, 29, 1108–1119. [Google Scholar] [CrossRef] [PubMed]
- Parikh, A.; Atreya, C.; Korn, W.M.; Venook, A.P. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. J. Natl. Compr. Canc Netw. 2017, 15, 3–8. [Google Scholar] [CrossRef]
Gender | Values | LCC n * = 75/26/101 | RCC n ** = 49/31/80 | Total n *** = 124/57/181 | p Value 1 |
---|---|---|---|---|---|
Male | average (SD) | 62.9 (9.1) | 62.6 (9.8) | 62.8 (9.3) | 0.833 |
min–max | 30–75 | 36–76 | 30–76 | ||
Female | average (SD) | 57.6 (10.4) | 59.5 (12.8) | 58.6 (11.7) | 0.553 |
min–max | 37–79 | 21–76 | 21–79 | ||
All | average (SD) | 61.6 (9.6) | 61.4 (11.1) | 61.5 (10.3) | 0.902 |
min–max | 30–79 | 21–76 | 21–79 | ||
p value 1 | 0.015 | 0.227 | 0.011 |
Parameters | Values | LCC n = 101 | RCC n = 81 | p Value 1 |
---|---|---|---|---|
Pathohistological type of tumor | Mucinous | 3 (3.0%) | 15 (18.8%) | 0.001 |
NOS | 97 (96.0%) | 63 (78.8%) | ||
Singnet ring cell | 1 (1.0%) | 2 (2.5%) | ||
Differentiation | Good | 15 (14.9%) | 7 (7.8%) | 0.031 |
Moderate | 75 (74.3%) | 53 (66.2%) | ||
Poor | 11 (10.9%) | 20 (25.0%) | ||
Resection margins | R0 | 85 (84.2%) | 72 (90.0%) | 0.442 |
R1 | 6 (5.9%) | 4 (5.0%) | ||
Palliative surgery | 10 (9.9%) | 4 (5.0%) | ||
Tumor infiltration lymphocyte | Dense | 19 (18.8%) | 11 (13.8%) | 0.176 |
Poor | 23 (22.8%) | 28 (35.0%) | ||
Moderate | 59 (58.4%) | 41 (51.2%) | ||
Stage at diagnosis | II | 13 (12.9%) | 15 (18.8%) | 0.283 |
III | 39 (38.6%) | 35 (43.8%) | ||
IV | 49 (48.5%) | 30 (37.5%) | ||
No. of examined LN | Average (SD) | 14.4 (8.7) | 18.2 (9.6) | 0.003 |
Min–max | 0–40 | 0–50 | ||
No. of positive LN | Average (SD) | 4.19 (4.7) | 5.29 (5.8) | 0.414 |
Min–max | 0–25 | 0–25 | ||
No. of metastatic sites | Average (SD) | 1.37 (0.66) | 1.60 (0.79) | 0.035 |
Min–max | 1–5 | 1–4 | ||
Lymph node involvement | Present | 6 (5.9%) | 3 (3.8%) | 0.742 |
Lymphovascular invasion | Present | 76 (75.2%) | 55 (68.8%) | 0.332 |
Perineural invasion | Present | 64 (63.4%) | 50 (62.5%) | 0.905 |
Ileus | Present | 28 (27.7%) | 24 (30.0%) | 0.737 |
Metastatic sites | Liver | 73.9% | 72.5% | 0.908 |
Lung | 20.8% | 22.5% | 0.781 | |
LN of abdomen | 12.9% | 25.0% | 0.036 | |
Local recurrence | 9.9% | 6.2% | 0.376 | |
LN of pelvis | 5.0% | 11.2% | 0.115 | |
Carcinosis of peritoneum | 3.0% | 8.9% | 0.091 | |
LN of thorax | 1.0% | 7.5% | 0.062 | |
Ovary | 3.0% | 1.2% | 0.785 | |
Bones | 2.0% | 1.2% | 1.000 | |
Adrenal gland | 2.0% | 1.2% | 1.000 | |
Brain | 1.0% | 1.2% | 1.000 | |
Urinary bladder | 2.0% | 0.0% | 0.582 | |
Prostate | 1.0% | 0.0% | 1.000 | |
Pancreas | 1.0% | 0.0% | 1.000 |
Line of Therapy | LCC n = 101 | RCC n = 80 | Total n = 181 | p Value 1 |
---|---|---|---|---|
II | 3 (3.0%) | 5 (6.2%) | 8 (4.4%) | 0.162 |
III | 88 (87.1%) | 72 (90.0%) | 160 (88.4%) | |
IV | 10 (9.9%) | 3 (3.8%) | 13 (7.2%) |
Predictors in CRC | B | SE | p 1 | Exp(B) | 95% CI |
---|---|---|---|---|---|
Mucinous adenocarcinoma | 0.990 | 0.269 | <0.001 | 2.69 | 1.59–4.56 |
Right localization of primary tumor | 0.375 | 0.164 | 0.022 | 1.46 | 1.06–2.01 |
Perineural invasion | 0.355 | 0.167 | 0.034 | 1.43 | 1.03–1.98 |
Resection margins end palliative surgery | 0.518 | 0.263 | 0.049 | 1.68 | 1.02–2.81 |
Predictors in LCC | B | SE | p 1 | Exp(B) | 95% CI |
---|---|---|---|---|---|
Perineural invasion | 0.468 | 0.225 | 0.038 | 1.60 | 1.03–2.48 |
Predictors in RCC | B | SE | p 1 | Exp(B) | 95% CI |
Mucinous adenocarcinoma | 1.136 | 0.304 | <0.001 | 3.12 | 1.72–5.66 |
Predictors in CRC | B | SE | p 1 | Exp(B) | 95% CI |
---|---|---|---|---|---|
Mucinous adenocarcinoma | 0.927 | 0.270 | 0.001 | 2.53 | 1.49–4.29 |
Right localization of primary tumor | 0.471 | 0.165 | 0.004 | 1.60 | 1.16–2.21 |
Parameters | Characteristics | Not Responded n = 79 | Good Response n = 102 | p Value 1 |
---|---|---|---|---|
LPT | Right | 49 (61.2%) | 31 (30.8%) | <0.001 |
Left | 30 (29.7%) | 71 (70.3%) | ||
Pathohistological type of tumor | NOS, SRCC | 64 (39.3%) | 99 (60.7%) | 0.001 |
Mucinous | 15 (83.3%) | 3 (16.7%) | ||
Differentiation | Good | 7 (31.8%) | 15 (68.2%) | 0.233 |
Moderate, poor | 72 (45.3%) | 87 (54.7%) | ||
Stage of disease | II | 11 (39.3%) | 17 (60.7%) | 0.613 |
III, IV | 68 (44.4%) | 85 (55.6%) | ||
No. examined LN | <11 | 18 (34.6%) | 34 (65.4%) | 0.120 |
>12 | 61 (47.3%) | 68 (52.7%) | ||
Involved LN | No | 16 (36.4%) | 28 (63.6%) | 0.263 |
Yes | 63 (46.0%) | 74 (54.0%) | ||
Resection margins and palliative surgery | R0 | 69 (43.9%) | 88 (56.1%) | 0.541 |
R1, R2 | 10 (41.7%) | 14 (58.3%) | ||
LVI | No | 20 (40.0%) | 30 (60.0%) | 0.188 |
Yes | 59 (45.0%) | 72 (55.0%) | ||
PNI | No | 25 (37.3%) | 42 (62.7%) | 0.834 |
Yes | 54 (47.4%) | 60 (52.6%) | ||
TIL | Poor, moderate | 25 (49.0%) | 26 (51.0%) | 0.361 |
Dense | 54 (41.5%) | 76 (58.5%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Radić, J.; Nikolić, I.; Kolarov-Bjelobrk, I.; Vasiljević, T.; Djurić, A.; Vidović, V.; Kožik, B. Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia. J. Pers. Med. 2024, 14, 879. https://doi.org/10.3390/jpm14080879
Radić J, Nikolić I, Kolarov-Bjelobrk I, Vasiljević T, Djurić A, Vidović V, Kožik B. Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia. Journal of Personalized Medicine. 2024; 14(8):879. https://doi.org/10.3390/jpm14080879
Chicago/Turabian StyleRadić, Jelena, Ivan Nikolić, Ivana Kolarov-Bjelobrk, Tijana Vasiljević, Aleksandar Djurić, Vladimir Vidović, and Bojana Kožik. 2024. "Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia" Journal of Personalized Medicine 14, no. 8: 879. https://doi.org/10.3390/jpm14080879